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2Abstract.
Accelerator mass spectrometry (AMS) is currently one of the most sensitive methods 
available for the trace detection of DNA adducts and is particularly valuable for 
measuring adducts in humans or animal models. However, the standard approach requires 
administration of a radiolabeled compound. As an alternative, we have developed a 
preliminary 14C-postlabeling assay for detection of the highly mutagenic O6-MedG, by 
AMS. Procedures were developed for derivatizing O6-MedG using unlabeled acetic 
anhydride. Using conventional LC-MS analysis, the limit of detection for the major 
product, triacetylated O6-MedG, was 10 fmoles. On reaction with 14C-acetic anhydride, 
using a specially designed enclosed system, the predominant product was 14C-di-acetyl 
O6-MedG. This change in reaction profile was due to a modification of the reaction 
procedure, introduced as a necessary safety precaution. The limit of detection for 14C-di-
acetyl O6-MedG by AMS was determined as 79 attomoles, ~18,000 fold lower than that 
achievable by LSC. Although the assay has so far only been carried out with labeled 
standards, the degree of sensitivity obtained illustrates the potential of this assay for 
measuring O6-MedG levels in humans. 
3Introduction
The frequent occurrence of methylated bases in DNA suggests that exposure to alkylating 
agents is a common event 1. N-Methyl Nitroso compounds (NOCs) are a large group of 
chemicals which are known to methylate DNA and can be found in a number of 
environmental sources, such as the diet, through the consumption of smoke-cured fish, 
meat and beer 2, whilst N-nitrosodimethylamine (NDMA) and 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) are present in cigarette smoke 3. Relatively small 
population subgroups working in the chemical manufacturing industry suffer 
occupational exposure to weakly genotoxic methylating agents such as dimethyl sulphate 
(DMS) and methyl bromide, which is also used as a fumigant 1. In addition, DNA 
continually suffers damage from endogenous sources of methylating compounds, with a 
possible candidate being S-adenosylmethionine 4. Nitrosation products of naturally 
occurring compounds, such as poly- or monoamines and peptides 5, 6 are also known to 
introduce O6-methyldeoxyguanosine (O6-MedG) into DNA 6. O6-MedG is a pre-
mutagenic lesion in both bacteria 7 and mammalian cells 8, as shown by the presence of 
mutations induced in cells treated with methylating agents, such as N-methyl-N-
nitrosourea and N-methyl-N’-nitro-N-nitrosoguanidine. Studies utilizing plasmids 
containing a single site-specific adduct have confirmed that O6-MedG is able to miscode, 
directing the introduction of the incorrect pyrimidine as its complementary base, when 
replicated in E. coli 9,10, resulting in the signature G → A transition mutation of alkylating 
damage 11. Evidence that O6-MedG may play an important role in the initiation of 
carcinogenesis comes from the frequent discovery of GC→AT mutations in the ras 
oncogene and p53 tumour suppressor gene of tumours induced in rodents 12 by 
4methylating agents such as NDMA. If O6-MedG is not repaired prior to replication, the 
resulting transition mutation may lead to cell death 13, sister chromatid exchanges 14, 
chromosomal aberrations 15 and malignant transformation 16.
A number of methods have been described for the detection and quantitation of O6-MedG 
after exposure to various alkylating agents. Levels of O6-MedG have been measured in 
DNA from rats treated with N-methyl-N'-nitro-N-nitrosoguanidine and NDMA, using 
immunoassays 17 and the ATase repair assay 18, respectively. In humans, background 
levels of approximately 1 O6-MedG/108 nucleotides have been detected in DNA of 
healthy individuals isolated from various tissues, using the repair assay 19, 20. Whilst these 
two approaches are both highly specific, they are not particularly sensitive; therefore the 
development of an assay with improved sensitivity that retains the specificity of the 
current methods would be extremely valuable for the detection of O6-MedG in human 
subjects.
Currently, accelerator mass spectrometry (AMS) is one of the most sensitive methods 
available for the detection of DNA adducts, typically offering at least 10-100 fold 
improvements in sensitivity over techniques such as 32P-postlabeling 21. Concentrations 
of long-lived, radioisotopes, such as 14C, can be measured by AMS at attomole levels, 
which equates to the detection of as little as 1-10 DNA adducts/1012 nucleosides formed 
by a 14C-labeled chemical 22. The most common experimental approach utilising AMS in 
human studies has been to administer a 14C-labeled compound of interest, then measure 
the extent of binding to DNA and protein, or the production of metabolites. This standard 
5approach is dependent on availability of 14C-labeled compounds and obtaining the ethical 
and radiological approval to administer these to animals or humans, which may not 
always be possible.
The concept of 14C-postlabeling as a means of adduct detection, would exploit the 
sensitivity of AMS without the need to administer a radioisotope to humans 23. 
Development of 14C-postlabeling assays for specific adducts could have a major impact 
in human biomonitoring, making it possible to conduct large population based studies to 
investigate the formation of low levels of adducts without prior administration of [14C]-
labeled chemicals. This would enable the assessment of individual variation and 
relationships between particular exposures and risk to be established. The general 
procedure involves isolation of specific adducts from DNA via enzymic digestion, 
followed by an enrichment step and subsequent addition of 14C-labeled groups on to the 
adduct. 14C-Labeled adducts can then be separated from other components of the reaction 
mixture by HPLC and quantified by AMS analysis. To date there is only a single reported 
study of AMS postlabeling, which describes the development of an assay for specifically 
quantifying benzo[a]pyrene DNA adducts formed in vitro 24. In the current study, 
methods have been developed and optimised for 14C-postlabeling O6-MedG adducts and 
the limits of detection determined using AMS. Comparisons have also been made to more 
conventional adduct detection methods such as liquid scintillation counting (LSC) and 
liquid chromatography-mass spectrometry (LC-MS) analysis.
Materials and Methods
6[1-14C]-Acetic anhydride (185 MBq/mmol) was purchased from ICN pharmaceuticals 
(Basingstoke, UK), bottled solvents for use in the AMS laboratory were purchased from 
Fisher (Loughborough, UK) and all other chemicals were purchased from Sigma-Aldrich 
(Poole, UK). 
General Instrumentation and Methods.
HPLC Analysis of Reaction Products  
HPLC separation of compounds with UV detection was carried out on a Gilson 
instrument comprised of model 305 pumps, a 805 nanometric module and a 811b mixer 
(Anachem, Luton, Bedfordshire, UK). Compounds were injected using a 200 μl loop, 
onto a 250 x 4.6 mm, 5µ, Luna C18(2) column (Phenomenex, Macclesfield, Cheshire, 
UK) operated at a flow rate of 1 ml/min and detected using a diode array detector, 1000s 
(Applied Biosystems, Warrington, Cheshire, UK). This HPLC system was specifically 
designated for radioactive applications, whilst a second HPLC system situated in the 
AMS laboratory was used solely for the separation of samples containing amounts of 14C 
below the limit of detection for LSC (~ 25 dpm). This Jasco instrument was comprised of 
intelligent HPLC pumps (PY-1580) and dynamic mixer (HG-1580-32). Samples were 
placed in screw cap vials (as above) and injected by an intelligent sampler (AS-1555) 
with a 200 μl loop, onto a 250 x 4.6 mm, 5µ, Luna C18(2) column at a flow rate of 1
ml/min. Compounds were detected using a multiwave detector (MD-1510, Jasco, 
Chelmsford, Essex, UK) set at 254 nm. Method 1: Reaction products were separated with 
a gradient of HPLC grade water (A) and MeOH (B) (0-5 min, 5% B, 5-30 min, 5-80% B, 
30-35 min, 80-5% B, 35-45 min, 5% B) and UV absorbance was monitored at 254 nm. 
7Method 2: Reaction products were separated using a gradient of HPLC grade H2O (A) 
and MeOH (B) (0-5 min, 5% B, 5-26 min, 5-62% B, 26-33 min, 62% B, 33-35 min, 62-
70% B, 35-40 min, 70-5% B, 40-45 min, 5% B) and detected by UV at 254 nm on the 
system designated for radioactive use. Method 3: All samples processed for AMS 
analysis were separated on the Jasco HPLC system in the AMS laboratory using the 
conditions described in Method 2.
Mass Spectrometry Analysis of Reaction Products. 
Positive ion electrospray analyses of products formed in the small-scale acetylation 
reactions were performed by continuous infusion of samples using a Harvard Apparatus 
model 22 syringe pump (Harvard Apparatus, Edenbridge, UK) into an Autospec Ultima-
Q mass spectrometer (Micromass, Manchester, UK). Analysis by fast atom bombardment 
mass spectrometry was performed on a 70-SEQ mass spectrometer (Micromass, UK). A 
glycerol matrix was used and analyses were conducted in positive ionisation mode. LC-
MS quantitation of reaction products was performed on a Quattro BioQ instrument 
(Micromass, UK) equipped with a pneumatically assisted electrospray source. The 
instrument was tuned using an O6-MedG adduct standard, which was infused using a 
Harvard syringe pump at a rate of 10 μl/minute. Analysis was carried out in the positive 
ion mode with a source temperature of 110ºC. Samples were introduced after HPLC 
separation using a Varian 9012 LC pump (Varian, Walton-on-Thames, Surrey, UK) and a 
linear gradient of methanol in water (0 min, 20 % MeOH, 20 min, 50 % MeOH).
1H-NMR Analysis.
8Samples were redissolved in d6-acetone prior to 1H-NMR analysis, performed on a 
Bruker ARX 250 spectrometer (Bruker Biospin Ltd, Coventry, UK), operating at 
250MHz. 
Synthesis of tri-acetyl O6-MedG standard.
A method was developed for the acetylation of O6-MedG with acetic anhydride which 
was optimised to ensure consistent addition of the maximum number of acetyl groups 
onto the adduct, as shown in Figure 1. This standard was then used to establish the limits 
of detection for this adduct using UV and MS as the detection methods. This was a small-
scale reaction (method A below), conducted using unlabeled acetic anhydride and it was 
hoped that this procedure could ultimately be employed in the 14C-postlabeling assay. In 
comparison, a second method (B) is also described which was used to produce a synthetic 
standard of tri-acetyl O6-MedG on a large-scale.
A. Small scale acetylation: O6-MedG, (10 mg, 35.5 nmoles), was dissolved in anhydrous 
pyridine (20 µl) and reacted with acetic anhydride (5 µl, 53 mmoles) at 100 ºC for 1 h. 
The acetylated derivative was isolated by HPLC separation, using Method 1, and eluted 
at 27.2 min. ESI-MS analysis of the reaction product showed m/z values of 208, 
equivalent to [mono-acetyl O6-MedG + H]+ and 408, consistent with [tri-acetyl O6-MedG 
+ H]+. To further confirm the structure of the tri-acetylated O6-MedG, which was formed 
in > 90% yield, a synthetic standard was produced, for complete characterisation, using 
an alternative method (B). 
9B. Large-scale synthesis of tri-acetyl O6-MedG: Tri-acetyl-dG, (640 nmoles), 
previously synthesised in this laboratory, based on a method by Gaffney et al. 25 was 
dried three times by evaporation with toluene, then dissolved in 50 ml dichloromethane 
(DCM) containing mesitylene sulphonyl chloride (500 mg), 4-dimethylaminopyridine 
(DMAP, 20 mg) and triethylamine (TEA, 500 ml) and reacted at room temperature until 
the solution turned yellow (~ 2 h). Quinuclidine (280 mg) was then added and the 
reaction continued for ~ 1 h until the solution darkened. Methanol (1.5 ml) and 1,8-
diazabicyclo(5,4,0)undec-7-ene (600 ml), were added and the reaction was left at room 
temperature for a further 1 h. The production of tri-acetyl O6-MedG was confirmed by 
thin-layer chromatography analysis of the reaction mixture, which was then concentrated. 
The residue was dissolved in 50 mM potassium phosphate buffer pH 6.5 (10 ml), 
extracted twice with DCM and purified by flash column chromatography on silica gel 
using a mobile phase of 30% MeOH in DCM. FAB-MS (m/z 208 and 408) and 1H-NMR 
(CDCl3) δ 2.2 (d, 6, 2 x COCH3), 2.6 (m, 4, H2’, NCOCH3), 3.0 (m, 1, H2”), 4.3 (s, 3, 
OCH3), 4.4 (m, 3, H5’, H5”, H3’), 5.5 (m, 1, H4’), 6.4 (m, 1, H1’), 8.0 (m, 2, NH, H8) 
confirmed the product as tri-acetyl O6-MedG. Fractions containing the desired product 
were combined and evaporated to dryness, giving 30 mg (11.5 %) yield. 
Reaction of 14C-acetic anhydride with O6-MedG
14C-Acetic anhydride is volatile; therefore care was taken during the acetylation 
procedure to guarantee that it was contained. For this purpose, a special drying system
was developed to ensure the evaporation of reaction products was enclosed and any 
excess 14C-acetic anhydride was contained. In order to synthesise a standard of 14C-tri-
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acetyl O6-MedG in the highest yield possible, a small number of acetylation reactions
were performed and the major products pooled, as this method was more efficient than a 
larger-scale reaction. 14C-Acetic anhydride (18.5 MBq), was transferred from a breakseal 
vial (as supplied) into anhydrous pyridine (160 μl, dried over molecular sieves). Aliquots 
of O6-MedG (8 x 1 μg), previously dried under nitrogen, were each redissolved in 
approximately of the 21 ml radioactive solution (12.5 mmoles acetic anhydride). The 
reactions were incubated in a heating block for 2.5 h at 100°C, cooled on ice, then 
quenched by the addition of 50% MeOH (40 ml). The reactions were pooled into two 
vials and dried in a diazomethane generator, which had been adapted into a drying 
chamber, with a cold trap and a succession of further traps joined to a vacuum pump, as 
illustrated in Figure 2. The contents of each vial were dissolved in 20% aqueous MeOH 
(1 ml) and analysed using HPLC Method 2. The fractions containing the major product 
from the reactions were collected, dried and quantitated by LSC.
Measurement of samples by LSC.
LSC was performed on a Beckman LS 6500 scintillation system (Beckman Coulter, 
Buckinghamshire, UK). Hydroflour scintillation fluid (5 ml) (National Diagnostics, Hull, 
UK) was added to each fraction and disintegrations per minute were counted for 10 min. 
The ambient background level was determined by measuring scintillation fluid alone, and 
was found to be ~25dpm (n = 3). This value was checked each time the instrument was 
operated. 
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Characterisation of 14C-labeled product
According to HPLC analysis, the major product of the 14C-acetylation reaction described 
above did not correspond to the tri-acetyl O6-MedG produced in the unlabeled acetylation 
reaction. Therefore, in order to determine the identity of this product, a reaction was 
performed using the same transfer procedure as required for the 14C-reaction but using 
unlabeled acetic anhydride, to produce a standard, which could then be characterised. 
Acetic anhydride was transferred into pyridine and O6-MedG was redissolved using this 
mixture, then incubated at 100 ºC for 2.5 h. The reaction was stopped with 50% aqueous 
MeOH and dried under nitrogen. The reaction products were separated by HPLC, using 
Method 2 and the fraction containing the peak corresponding to the major product of the 
14C-postlabeling reaction was collected and freeze-dried. This was then analysed by 
FAB-MS (m/z 166 [O6-methylguanine + H]+ and 366 [di-acetyl O6-MedG + H]+) and 1H-
NMR (acetone-d6) δ 2.0 (m, undistinguishable), 2.5 (m, 1, H2’), 3.1 (m, 1, H2”), 3.9 (s, 1, 
OCH3), 4.4 (m, 3, H5’, H5”, H3’), 5.4 (d, 1, H4’), 5.7 (s, 2, NH2), 6.3 (t, 1, H1’), 7.9 ( s, 1, 
H8) and determined to be di-acetyl O6-MedG. In addition to the major product, tri-acetyl 
O6-MedG was also formed in approximately 40% yield, which is considerably lower than 
the proportion generated using the original acetylation method (method A above), 
indicating that incorporation of the transfer step accounts, at least in part, for the 
difference in reaction profile.  
LC-MS assay for analysis of acetylated O6-MedG.
Authentic standards of O6-MedG (20 μl) were injected onto a 250 x 4.6 mm Luna C18(2) 
column (Phenomenex) and detected by selected ion recording (SIR). To determine the 
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limit of detection of O6-MedG adducts using LC-MS, aliquots of O6-MedG (5 fmoles to 
300 pmoles) were dried under nitrogen, redissolved in anhydrous pyridine (20 ml) and d6-
acetic anhydride (C4D6O3, 5 ml), then incubated at 100°C for 1 h. Reactions were stopped 
by the addition of 50% aqueous MeOH (20 ml) and evaporated to dryness under nitrogen. 
The reactions were then redissolved in 20% MeOH (20 μl) and analysed directly by LC-
MS using unlabeled tri-acetyl O6-MedG as an internal standard. In addition, a standard of 
deuterated tri-acetyl O6-MedG was analysed by 1H-NMR: (D2O), δ 2.7 (m, 1, H2’), 3.1 (q, 
1, H2”), 4.05 (s, 3, OCH3), 4.3 (m, 3, H5’, H5”, H3’), 5.5 (s, 1, H4’), 6.5 (m, 1, H1’).
Limit of Detection of 14C-Di-acetyl O6-MedG by LSC.
To ascertain the limit of detection of isolated 14C-acetylated adduct by LSC, a standard of 
14C-di-acetyl O6-MedG (58 nmoles in 1 ml of H2O) was diluted to provide 9 samples, 
spanning a concentration range covering four orders of magnitude. The dilutions were 
quantitated by LSC and were used to plot a calibration line (Figure 3). The same samples 
were also subject to HPLC separation (Method 2), and the fraction corresponding to 14C-
di-acetyl O6-MedG collected and quantitated by LSC for each dilution. The dpm values 
were converted to fmoles of labeled adduct, and used to construct a curve for 14C-di-
acetyl O6-MedG. 
Limit of Detection of 14C-Di-acetyl O6-MedG by AMS
To determine the limits of detection of 14C-di-acetyl O6-MedG by AMS, samples of 
labeled adduct were diluted to produce concentrations below the limit of detection by 
LSC. Precautions were taken to prevent contamination of the AMS preparation laboratory 
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26, therefore prior to analysis, samples were screened by LSC to ensure they did not 
contain measurable amounts of radioactivity above background levels. Duplicate samples 
of each dilution were subject to HPLC separation (Method 3) and one-minute fractions 
were collected throughout the entire run. The dilutions were injected from lowest to 
highest concentration to avoid cross contamination due to carry-over, with two blank 
injections of dH2O in between samples. The HPLC fractions expected to contain the 14C-
di-acetyl O6-MedG peak, eluting at 27 min, were submitted for AMS analysis, along with 
fractions immediately preceding the adduct (25 and 26 min). Analysis of a 28 min 
fraction revealed a low level of 14C, similar to the 26 min fraction, confirming that the di-
acetylated adduct elutes in the 27 min fraction.
Analysis of samples by AMS
AMS analysis of samples was carried out at Lawrence Livermore National Laboratory, 
according to the standard protocol 27. Each sample was evaporated to dryness in a 
Speedvac then the residue was redissolved in 20% aqueous MeOH (1 ml). Half of each 
sample was added to a quartz tube with 100% tributyrin (1 µl), and was converted to 
graphite as described by Ognibene et al., 28 then was analysed by AMS. Each graphite 
sample was analysed up to seven times for radiocarbon content by AMS or until the 
measurement variation was within ± 5%. The resulting data was converted from fraction 
modern to attomoles of O6-MedG, taking into consideration the specific activity of the 
14C-acetic anhydride and the fraction labeled 29.
RESULTS 
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Acetylation of O6-MedG.
Reaction of O6-MedG with acetic anhydride yielded tri-acetyl O6-MedG as the major 
reaction product (>90% yield), as indicated by ESI-MS analysis, which demonstrated the 
presence of quasi molecular ions at m/z 208 [mono-acetyl O6-MeG + H]+ and the major 
product, 408 [tri-acetyl O6-MedG + H]+, in addition to the corresponding Na+ and K+
adduct ions. A standard of this compound was produced in a larger-scale reaction and 1H-
NMR analysis confirmed the structure as having three acetyl groups on O6-MedG, with 
one attached to the NH of guanine and the remaining two to the deoxyribose OH groups. 
Limit of Detection of Tri-acetyl O6-MedG by LC-MS.
To determine the limit of detection of tri-acetyl O6-MedG by LC-MS, deuterated acetic 
anhydride was used to synthesise isotope-labeled derivatised adducts and the unlabeled 
tri-acetyl O6-MedG standard was employed as an internal standard. The assay was 
conducted in this manner as a pure unlabeled tri-acetyl O6-MedG standard had previously 
been synthesised, whereas a deuterated standard was not available at that time.
Initial LC-MS (SIR) analysis of the deuterated product from the acetylation reaction of 
300 pmoles O6-MedG did not reveal any ions at m/z of 417 and 439, which would be 
consistent with protonated d9-tri-acetyl O6-MedG and its sodiated ion. Therefore, a total 
ion scan of the reaction sample was carried out using tri-acetyl O6-MedG as an internal 
standard. The resulting mass spectrum showed a sodiated molecular ion for tri-acetyl O6-
MedG with m/z 430, as expected, but also present were ions at m/z 418, 440 and 456, 
consistent with the addition of a proton, along with sodium and potassium ions 
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respectively, to the original predicted [M+H]+ value (data not shown). This means that 
the compound has a molecular weight of 417, which is one mass unit higher than 
expected after the addition of three deuterated acetyl groups. 1H-NMR analysis suggests 
that deuterium exchange has occurred at the H8 position, since there is no peak visible for 
this proton in the spectrum (data not shown). This would account for the additional mass 
unit and consequently d10-tri-acetyl O6-MedG was utilised in this assay. Reactions were 
analysed by LC-MS using SIR detection, to ascertain the limit of detection. The ratio of 
peak areas of d10-tri-acetyl O6-MedG formed in reactions to unlabeled internal standard 
was used to construct a calibration line, as shown in Figure 3. The relationship between 
d10-tri-acetyl O6-MedG and the internal standard was linear, as expected, and the limit of 
detection was calculated as 10 fmoles of adduct, taking into account a signal to noise 
ratio of 1:5 (n = 3). 
Acetylation of O6-MedG using 14C-acetic anhydride.
The use of 14C-acetic anhydride as the labeling agent required that the acetylation method 
be altered as a transfer step had to be incorporated to remove the reagent from its 
supplied vial and an enclosed drying method was also necessary to prevent any 14C-
labeled material from escaping during evaporation. An unlabeled standard was prepared 
using this method, which had the same HPLC retention time as the major labeled reaction 
product and was characterised by FAB-MS and 1H-NMR analysis. FAB-MS 
demonstrated that the major reaction product was di-acetyl O6-MedG, as shown by the 
presence of quasi molecular ions at m/z 366 [di-acetyl O6-MedG + H]+ and m/z 166 [O6-
MeG + H]+. This is further confirmed by 1H-NMR, which indicates the two acetyl groups 
are present on the deoxyribose, due to the absence of OH protons in the NMR spectrum.
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HPLC separation of the 14C-acetylation reaction revealed that the major product was di-
acetyl O6-MedG (formed in 38 % yield), as the retention time was identical to that of the 
synthesised unlabeled standard. Importantly, no tri-acetyl O6-MedG was detectable, and 
as the reaction of O6-MedG with 14C-acetic anhydride failed to generate any of the
desired tri-acetylated derivative, di-acetyl O6-MedG was consequently used in further 
development and application of the assay. The 14C-di-acetyl O6-MedG standard was 
collected by HPLC separation of the reaction products, concentrated under nitrogen, 
further purified by HPLC, and quantitated by LSC.
Limit of Detection of di-acetyl O6-MedG by LSC after HPLC isolation
A linear relationship can be observed between the amount of 14C-di-acetyl O6-MedG and 
radioactivity contained in dilutions above a limit of detection of 745 fmoles, as measured 
by LSC. In comparison, further HPLC isolation of the adduct contained in these same 
dilutions followed by LSC quantitation increases the limit of detection to 1.4 pmoles, due 
to losses incurred during HPLC (Figure 4).
Limit of detection of di-acetyl O6-MedG by AMS
For samples analysed by AMS, the total amount of 14C contained in each submitted 
sample and control was calculated from the fraction Modern values, to construct a limit 
of detection curve for this adduct. The theoretical limit of detection, defined as the mean 
blank (solvent control) plus 3 times standard deviation of the mean (n = 5), is dependent 
on the background level of 14C in the HPLC fractions collected from blank runs. As 
17
shown in Figure 5, the limit of detection was equivalent to 79 attomoles of di-acetyl O6-
MedG in a 1 ml HPLC fraction. The limit of detection is calculated from the amount of 
14C present in the blank runs performed in between each sample run, which is influenced 
by any 14C-labeled chemicals/ solvents injected onto the system. 
Discussion
The ultimate aim of this study was to develop methodology for the derivatisation of O6-
MedG by 14C-postlabeling, generating products that could be isolated and quantified by 
AMS. For comparison purposes the limits of detection attainable by more conventional 
methods for this adduct were also determined and the results clearly highlight the greater 
sensitivity of AMS.
The strategy taken was to establish a reaction protocol using unlabeled reagents for 
derivatising O6-MedG by acetylation, then to adapt this for use with 14C-acetic anhydride. 
The preferred reaction product should contain as many acetyl groups as possible, which 
based on initial reactions would be the tri-acetylated derivative, since for AMS analysis it 
is desirable to incorporate as many 14C atoms as possible to maximise assay sensitivity. 
However, which specific acetylated derivative is chosen for quantitation purposes in the 
assay is not so important, providing that the reactions and yields of the derivative are 
consistent and the results reproducible, although derivatisation of two rather than three 
functional groups reduces the theoretical detection limits. This is particularly important 
with respect to assay efficiency, so as to allow losses due to acetylation and isolation of 
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the reaction products to be accounted for, and the level of adducts in a DNA sample 
accurately determined.
In a model reaction, LC-MS analysis was used to determine the limit of detection for 
deuterated tri-acetyl O6-MedG. The fact that d10-tri-acetyl O6-MedG was the major 
product of the acetylation reaction with d6-acetic anhydride appears to be caused by 
deuterium exchange at the H8 position, as evidenced by 1H-NMR analysis. Since acetic 
anhydride contains two stable methyl groups, the potential for donating a deuterium ion 
seems unlikely, although it is possible that acetic anhydride may tautomerise, thus 
releasing a deuterium ion available for exchange. It is also possible that the d6-acetic 
anhydride purchased may contain impurities or degradation products, such as acetic acid, 
which could more easily donate a deuterium ion. The level of derivatised adducts 
measured for this assay resulted in a linear calibration line (Figure 3), and the limit of 
detection was determined as 10 fmoles. 
Acetylation of O6-MedG with 14C-acetic anhydride yielded a change in the profile of 
reaction products, with di-acetyl O6-MedG formed as the major product, as characterised 
by FAB-MS and 1H-NMR using an unlabeled standard. Whilst the reason for this 
difference is not entirely clear, it is possible that since the newly incorporated transfer 
step was not performed under an anhydrous atmosphere, increased hydrolysis of the 14C-
acetic anhydride may account for the reduction in yield of the desired product. A further 
contributing factor could be the presence of impurities or unknown stabilising agents in 
the radiolabeled acetic anhydride that are not contained in the unlabeled reagent. As a 
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consequence of this finding and since this derivative was consistently demonstrated to be 
the major product, it was decided that this acetylated derivative would be used as the 
adduct form for quantitation by LSC and AMS in subsequent experiments. 
The limit of detection of 14C-di-acetyl O6-MedG by LSC was found to be 745 fmoles, 
determined by quantifying the 14C content in a series of diluted samples. Since in the final 
assay the labeled adduct will be purified by HPLC prior to AMS analysis, the effect of 
this step on the limit of detection was determined. On constructing a second calibration 
curve of 14C-concentration measured by LSC in the same dilutions after HPLC separation 
and collection of the appropriate fractions the limit of detection was found to be 1.4 
pmoles of adduct (Figure 4). This is approximately two-fold higher than the limit of 
detection achievable without HPLC. When dilutions containing less than 1.4 pmoles 14C-
di-acetyl O6-MedG were analysed, the fractions contained more radioactivity than the 
ambient background level of 25 dpm and therefore were above the limit of detection, 
most likely caused by the background contamination level on the HPLC. In this range the 
relationship between amount of adduct present and 14C measured was no longer 
proportional.
To determine the limit of detection by AMS, further serial dilutions of 14C-di-acetyl O6-
MedG were prepared down to attomole levels and checked by LSC to ensure that only 
samples below a background level of 25 dpm are handled in the AMS lab, to prevent 
contamination. These steps were taken as it is recommended that no more than 10 dpm 
should be injected onto a HPLC system using a semi-prep column, in order to prevent 
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contamination 26. AMS analysis of the HPLC purified 14C-diacetyl-O6-MedG fractions 
and random blank runs allowed the limit of detection to be determined. The amount of 
14C in each sample was converted into fmoles of di-acetyl O6-MedG by taking into 
account the fraction labeling. The assay limit of detection, defined in this study as the 
mean background level of 14C in blank fractions plus 3 times the standard deviation 30
was calculated as 79 attomoles of di-acetyl O6-MedG, which is approximately 9500 fold 
more sensitive than LSC, without a HPLC step (Figure 6). In comparison, Goldman et al. 
attained a theoretical limit of detection of 100 attomoles for their acetylated BPDE adduct 
standard 24. The maximum sensitivity attainable for this adduct should theoretically be 
greater because five 14C-acetyl groups are added, compared to two acetyls reacted with 
O6-MedG in this study. The chemistry employed in 14C-labeling protocols requires that 
every assay has to be specifically developed and optimised for each individual DNA 
adduct, as potential sites of acetylation are dependent on adduct structure. Therefore, 
whilst the general steps undertaken in this assay are similar to those described by 
Goldman et al. 24, the details are inherently different. A particular feature of the assay 
developed in this study is the design and use of an enclosed drying system, which enables 
14C-postlabeling to performed in any designated fumehood, without the need for a 
specific radioactive laboratory, whilst ensuring all excess radioactivity is converted to a 
non-volatile form and safely contained. 
Typical limits of detection for LC-MS are in the region of 1 adduct per 108 nucleosides 31, 
32 but more sensitive assays have been developed, for example a limit of detection for 
BPDE-dG of 0.3 adducts in 108 normal nucleotides has been described [33], and as low 
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as 1-2 adducts per 1010 nucleotides for etheno dA and dC adducts has been reported 34, 
using LC-MS/MS with MRM analysis. As technologies improve, the limits of detection 
for DNA adduct analysis using conventional mass spectrometry will become increasingly 
more sensitive and may eventually be comparable to those currently achieved with AMS. 
Whilst 32P-postlabeling is presently one of the most sensitive routinely used assays for the 
measurement of DNA adducts, and is generally more straightforward, than the 14C-
postlabeling assay presented here, the latter does offer several advantages: it is 
considerably more sensitive, does not suffer from artefacts since specific, known adducts 
are isolated and measured directly after labeling, and it is not limited by the half-life of 
14C, unlike the isotope 32P. In addition, the 14C-postlabeling assay should be easily 
adaptable for the measurement of any adduct regardless of size, including small alkyl 
adducts which can be difficult to detect by 32P-postlabeling 35.
The limit of detection is the lowest amount of adduct that can be reliably quantified using 
the current methodology. In practice however, adduct recovery throughout isolation 
digestion, labeling and clean-up procedures prior to HPLC purification will not be 100%, 
therefore the limit of detection, relative to the amount of O6-MedG in the original DNA 
sample, will actually be higher than this value. Typical recovery rates for the entire assay 
are in the order of 29 ± 10% and are relatively reproducible. Knowing the assay 
efficiency it is possible to more accurately estimate adduct levels in the starting sample. 
To conclude, a preliminary 14C-postlabeling assay has successfully been developed for 
the quantitation of O6-MedG by AMS. The assay has been demonstrated to be several 
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orders of magnitude more sensitive for the detection of this adduct than current 
conventional methods. However, the assay still needs to be fully validated and applied to 
the measurement of O6-MedG in DNA from exposed animals or humans to determine 
robustness and reproducibility. Initial studies indicate the assay should be sensitive 
enough to measure in the region of 1-10 O6-MedG adducts per 1012 nucleotides (data not 
shown), which is four orders of magnitude lower than adduct levels previously reported 
in human tissue 19. Ultimately this assay has enormous potential and with such improved 
sensitivity it should be possible to establish background levels of O6-MedG in human 
populations as a result of endogenous or environmental exposures.
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Figure Legends
Figure 1. Proposed sites of O6-MedG acetylation after reaction with acetic anhydride. On 
reaction with 14C-acetic anhydride however, a di-acetylated derivative is the major 
product with acetyls at the 3’(C)O and 5’(C)O positions of the sugar moiety (*). 
Figure 2. Containment apparatus designed to carry out 14C-postlabeling reactions in a 
closed environment. The evaporated 14C-acetic anhydride freezes onto the sides of the dry 
ice/acetone chamber [A], which on melting is safely collected [B]. Two additional traps 
are present as a further safety measure.
Figure 3. Typical LC-MS analysis of tri-acetyl O6-MedG using SIR (A). d10-Tri-acetyl 
O6-MedG was quantified using unlabeled tri-acetyl O6-MedG as the internal standard. 
The ratio of peak areas of the sodiated molecular ions (m/z = 440 and 430 for the 
deuterated and unlabeled tri-acetylated adduct respectively) was used to construct a 
calibration line as shown in (B), from which adduct levels could be determined. For each 
data point the mean of three different acetylation reactions was plotted. The limit of 
detection was determined to be 10 fmoles using this method.
Figure 4. HPLC separation of the 14C-postlabeling reaction products is shown in (A): 
peaks 1 and 2 correspond to pyridine and unreacted O6-MedG, 3 is 14C-mono-acetyl O6-
MedG, 4 and 5 are 14C-di-acetyl O6-MedG derivatives. Peak 5 was collected as the major 
product and used to determine limits of detection of 0.75 and 1.4 pmoles for LSC and 
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HPLC separation with LSC, respectively as shown in (B). Each dilution was measured 
twice.
Figure 5. Relationship between the amount of adduct injected onto the HPLC system and 
that detected in the appropriate fraction by AMS (n =2). The limit of detection of 14C-di-
acetyl O6-MedG (------) was determined to be 79 attomoles. 
Figure 6. Comparison of the detection limits of 14C-di-acetyl O6-MedG by methods used 
in this study, illustrating the sensitivity of AMS relative to conventional methods.
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Figure 5.
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